{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:09:25Z","timestamp":1789708165444,"version":"4.0.1"},"reference-count":43,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Eribulin is currently recommended for the treatment of patients with metastatic breast cancer (MBC) pre\u2010treated with taxanes and anthracyclines. The aim of the present study was to evaluate the effectiveness and safety of eribulin and its impact on health\u2010related quality of life in heavily pre\u2010treated patients with MBC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from MBC patients who had received eribulin\u2010based therapy at Beijing Cancer Hospital between January 2020 and July 2022 were analyzed retrospectively. Progression\u2010free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), adverse effects (AEs) and health\u2010related quality of life (HRQoL) were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 118 patients who had received eribulin to treat MBC were included. Median PFS was 4.2\u2009months and median OS had not been reached. The ORR was 13.6% (16\/118) and DCR was 75.4% (89\/118). The median PFS in patients who received eribulin in second\u2010line (26\/118), third\u2010line (29\/118), or fourth\u2010line or later (63\/118) was 4.5, 4.2, and 3.9\u2009months, respectively. The median OS in patients who received eribulin in third\u2010 or later line (<jats:italic>n<\/jats:italic>\u2009=\u200992) was 14.1\u2009months. Patients who received eribulin combination therapy had a significantly longer median PFS compared with those who received eribulin monotherapy (4.5 vs. 3.4\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.007) and there was a trend towards a longer median OS (not reached vs. 12.1\u2009months). The most common grade 3\u20134 adverse events were neutropenia (22.9%), leukocytopenia (13.6%) and asthenia\/fatigue (8.5%), without significant differences in safety between eribulin monotherapy and combination therapy. Quality of life was similar in patients who received eribulin monotherapy and combination therapy, except for cognitive function and nausea and vomiting symptoms, which were better with combination therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The present study suggests that eribulin\u2010based therapy is an effective treatment option and well tolerated for heavily pre\u2010treated patients with MBC. Eribulin combination therapy might improve PFS and HRQoL compared with eribulin monotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6301","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T09:40:02Z","timestamp":1688550002000},"page":"16793-16804","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness, safety, and impact on quality of life of eribulin\u2010based therapy in heavily pretreated patients with metastatic breast cancer: A real\u2010world analysis"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0589-8732","authenticated-orcid":false,"given":"Xinyu","family":"Gui","sequence":"first","affiliation":[{"name":"Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing) Department of Breast Oncology, Peking University Cancer Hospital &amp; Institute  Beijing, China 100142 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-4146","authenticated-orcid":false,"given":"Xu","family":"Liang","sequence":"additional","affiliation":[{"name":"Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing) Department of Breast Oncology, Peking University Cancer Hospital &amp; Institute  Beijing, China 100142 China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-647X","authenticated-orcid":false,"given":"Huiping","family":"Li","sequence":"additional","affiliation":[{"name":"Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing) Department of Breast Oncology, Peking University Cancer Hospital &amp; Institute  Beijing, China 100142 China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2022.03.02"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2020.02.01"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-74039-3_1"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-3-253"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-04-0345"},{"issue":"11","key":"e_1_2_13_7_1","first-page":"C38","article-title":"Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel\u2010resistant human cancer cells in vitro","volume":"6","author":"Kuznetsov G","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0360"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.3036"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4892"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.02.002"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0449-z"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3217-z"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01591-x"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3567-y"},{"issue":"4","key":"e_1_2_13_17_1","first-page":"364","article-title":"Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer","volume":"44","author":"Sang D","year":"2022","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211030210"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_13_21_1","volume-title":"The EORTC QLQ\u2010C30 Scoring Manual","author":"Fayers PM","year":"2001"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00991-6"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.09.011"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1670356"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32402"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-019-0367-x"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01613-6"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0324"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103375"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00439-5"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0163"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.012"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100054"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.08.008"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.80"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12407"},{"issue":"2","key":"e_1_2_13_38_1","first-page":"S40","article-title":"Taxane and epothilone\u2010induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24","author":"Tamburin S","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.39788"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1188\/13.CJON.S1.35-40"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06894-2"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2014.04.004"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-01920-0"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30569-0"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T09:46:40Z","timestamp":1711532800000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":43,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/cam4.6301"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6301","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"2023-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}